Combinations, methods and compositions for treating cancer
OwnerFrancis Lee, Roberto Weinmanninventors
Life of this patent
Estimating the term…
Abstract
The invention relates to a combination of BCR-ABL inhibitor, exemplified by ′N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide and/or other BCR/ABL inhibitors, and a stem cell selective cytotoxic, exemplified by (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile, hydrochloride salt, and or other stem cell cytotoxic agents, pharmaceutical compositions of the combination and to methods of using the pharmaceutical compositions in the treatment of oncological disorders.
Claims11
A method of treating cancer which comprises administering, in combination, to a host in need thereof a therapeutically effective amount of:
- (a) a stem cell selective cytotoxic agent or pharmaceutically acceptable salt thereof, and
- (b) at least one of a BCR/ABL inhibitor or pharmaceutically acceptable salt thereof.
A combination which comprises a therapeutically effective amount of:
- (a) a stem cell selective cytotoxic agent or pharmaceutically acceptable salt thereof, and
- (b) at least one of a BCR/ABL inhibitor or pharmaceutically acceptable salt thereof.
A method of treating cancer which comprises administering, in combination, to a host in need thereof a therapeutically effective amount of:
- (a) a compound of formula (II)
- or pharmaceutically acceptable salts thereof, and
- (b) and a compound of formula (I)
- or pharmaceutically acceptable salts or hydrate thereof.
Dependencies are inferred from the claim text.